Can I Take Omega-3 (EPA/DHA) with Cialis (Tadalafil)?

What Type of Interaction Exists Between Omega-3 and Tadalafil?

The interaction is pharmacodynamic, not pharmacokinetic. Tadalafil is metabolized almost entirely by hepatic CYP3A4 [1], and omega-3 fatty acids do not meaningfully inhibit or induce that enzyme at dietary or supplemental doses. That means fish oil will not raise or lower tadalafil blood levels.

Where the two overlap is in downstream physiology: both agents reduce blood pressure by separate mechanisms, and both carry mild antiplatelet properties. Understanding each mechanism separately makes the combined picture easier to manage.

Tadalafil's Mechanism

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), preventing breakdown of cyclic GMP in smooth-muscle cells lining penile and pulmonary vasculature [1]. The resulting vasodilation lowers peripheral vascular resistance, which produces a measurable drop in blood pressure. In the original approval trials, tadalafil 20 mg produced mean maximum decreases in systolic blood pressure of approximately 8 mmHg compared with placebo [2].

Omega-3's Mechanism

EPA and DHA reduce triglycerides primarily by suppressing hepatic VLDL synthesis and accelerating triglyceride clearance [3]. At the vascular level, they reduce thromboxane A2 synthesis in platelets, competing with arachidonic acid for cyclooxygenase, which partially explains their antiplatelet effect [4]. High-dose EPA also reduces inflammation via specialized pro-resolving mediators, an effect documented in the REDUCE-IT trial (icosapentaenoic acid 4 g/day, N=8,179) that contributed to a 25% relative reduction in major adverse cardiovascular events [5].

Separately, a 2014 meta-analysis of 70 randomized controlled trials (N=4,680 total participants) found that omega-3 supplementation reduced systolic blood pressure by a weighted mean of 1.52 mmHg across all doses, with the effect rising to approximately 4.5 mmHg at doses near 5.6 g/day [6].

Is the Blood-Pressure Overlap Clinically Meaningful?

For most men taking standard OTC omega-3 doses (1 to 2 g combined EPA+DHA per day), the additive blood-pressure effect on top of tadalafil is small and unlikely to cause symptomatic hypotension. The concern rises when omega-3 doses exceed 3 to 4 g/day or when tadalafil is combined with other antihypertensive agents.

Who Faces the Highest Risk

The FDA prescribing information for tadalafil explicitly warns that co-administration with nitrates is contraindicated due to severe hypotension risk [2]. Alpha-blockers represent a separate, labeled additive-hypotension risk. Omega-3 at standard doses is not in the same risk category as either of those drug classes, but a man already near the lower limit of normal blood pressure should monitor symptoms carefully after adding either agent.

Men on amlodipine, lisinopril, or similar antihypertensives who then add both tadalafil and high-dose omega-3 carry the highest theoretical burden of additive pressure reduction. A 2021 analysis of PDE5 inhibitor safety published in the European Heart Journal found that symptomatic hypotension with tadalafil was most common when two or more additional vasodilatory agents were present [7].

Practical Blood-Pressure Monitoring Steps

1. Record a resting sitting blood pressure before starting either supplement or medication.
2. Recheck at 4 weeks after reaching a stable dose of both agents.
3. Stop and contact your prescriber if systolic pressure falls below 90 mmHg or symptoms of dizziness appear.

Does Omega-3 Increase Bleeding Risk with Tadalafil?

Tadalafil itself carries minimal antiplatelet activity in standard clinical use. Omega-3 supplementation at doses above 3 g EPA+DHA per day can prolong bleeding time modestly, primarily through thromboxane A2 suppression [4]. The combination does not appear to produce clinically significant bleeding in otherwise healthy men based on available evidence.

What the Bleeding Data Actually Show

A review published in Prostaglandins, Leukotrienes and Essential Fatty Acids examined 19 studies on omega-3 and platelet function [4]. Doses below 3 g/day produced inconsistent effects on platelet aggregation. Doses above 3 g/day consistently reduced thromboxane B2 production, but whether that translated into clinically meaningful bleeding events was not established in most studies.

Tadalafil's effect on platelet function at therapeutic doses is not clinically significant based on its prescribing information [2]. No published trial to date has documented an increased rate of serious bleeding from the omega-3 plus tadalafil combination specifically.

When to Exercise Extra Caution

Men taking warfarin, aspirin, clopidogrel, or direct oral anticoagulants alongside tadalafil should report any plan to add high-dose omega-3 to their prescriber. The 2018 American Heart Association Science Advisory on omega-3 for cardiovascular disease noted that doses above 3 g/day from supplements "may cause clinically significant bleeding" in certain populations [8]. That threshold matters most in anticoagulated patients.

Pharmacokinetic Safety: Why Fish Oil Won't Change Your Tadalafil Levels

This is the question many men worry about most, and the answer is straightforward. Tadalafil is a CYP3A4 substrate with a half-life of approximately 17.5 hours [1]. Omega-3 fatty acids are not inhibitors of CYP3A4, CYP2C9, CYP2D6, or P-glycoprotein at concentrations achieved by dietary supplementation [9].

A 2005 pharmacokinetic study of fish oil and cytochrome P450 activity in healthy volunteers found no significant changes in the pharmacokinetic parameters of probe substrates after 4 weeks of fish oil supplementation at 3 g/day [9]. That means tadalafil's Cmax, area under the curve, and time to peak concentration should remain unchanged when omega-3 is co-administered.

No Dose Separation Needed

Because no pharmacokinetic interaction exists, there is no clinical need to separate the timing of tadalafil and omega-3 doses. Men may take their fish oil capsules at the same meal as tadalafil 5 mg daily (the dose used for BPH or daily ED treatment) without any predicted change in drug exposure [2].

Omega-3 and Cardiovascular Risk: Why Many Men Take Both

Men prescribed tadalafil for erectile dysfunction (ED) often carry overlapping cardiovascular risk factors. ED itself is now recognized as a vascular endothelial condition and an independent predictor of future major adverse cardiovascular events. A 2018 meta-analysis in JAMA Internal Medicine found that men with ED had a 43% higher risk of all-cause mortality and a 59% higher relative risk of cardiovascular events compared with men without ED [10].

Omega-3 supplementation in high-risk cardiovascular patients has a separate, evidence-based rationale. The REDUCE-IT trial showed that icosapentaenoic acid 4 g/day (Vascepa) on top of statin therapy reduced major adverse cardiovascular events by 25% relative risk reduction (hazard ratio 0.75, 95% CI 0.68 to 0.83, P<0.001) over a median 4.9-year follow-up [5]. STRENGTH (N=13,078), which used a different omega-3 formulation (EPA+DHA combination), did not show the same benefit, suggesting the cardiovascular effect may be specific to pure EPA [11].

A Practical Framework for Men on Both Agents

The following decision framework may help clinicians and patients discuss whether high-dose omega-3 is appropriate alongside tadalafil:

| Patient Profile | Omega-3 Dose | Tadalafil Dose | Monitoring Priority | |---|---|---|---| | Healthy male, no comorbidities | 1 to 2 g/day EPA+DHA | 5 to 20 mg as needed | Annual BP check | | Hypertensive, on one antihypertensive | 1 to 2 g/day EPA+DHA | 5 mg/day | BP check at 4 weeks | | High TG (>500 mg/dL), on statin | 4 g/day icosapentaenoic acid (Vascepa) | 5 mg/day | BP + LFT at 8 weeks | | On warfarin or anticoagulant | <3 g/day EPA+DHA | Any approved dose | INR within 2 weeks of dose change | | On nitrates | Any dose omega-3 | Contraindicated | N/A |

Triglyceride Effects: A Beneficial Overlap, Not a Concern

Both tadalafil and omega-3 may improve endothelial function through separate pathways, and neither worsens lipid profiles. Omega-3 at 2 to 4 g/day of EPA+DHA reduces fasting triglycerides by 20 to 30% in patients with hypertriglyceridemia, as established in a 2002 meta-analysis of 47 trials [3]. Tadalafil has no adverse effect on lipid panels at approved doses [2].

What This Means for BPH Patients

Tadalafil 5 mg daily is FDA-approved for benign prostatic hyperplasia. Men with BPH are often older and carry metabolic syndrome, which includes hypertriglyceridemia. Adding omega-3 to address elevated triglycerides while already on tadalafil 5 mg/day represents a sensible metabolic strategy with no pharmacokinetic conflict and manageable pharmacodynamic overlap.

The American Urological Association 2021 BPH guidelines note that lifestyle modifications, including dietary fat quality, should accompany pharmacotherapy for lower urinary tract symptoms [12]. Omega-3-rich diets align with that recommendation without requiring tadalafil dose changes.

What Dosing Guidelines Say

No major guideline specifically addresses the omega-3 plus tadalafil combination as a named drug-supplement interaction warranting a contraindication or dose adjustment. The FDA label for tadalafil lists CYP3A4 inhibitors (ketoconazole, ritonavir), nitrates, and alpha-blockers as the primary interaction concerns [2]. Omega-3 supplements are absent from that list.

The American Heart Association's 2019 science advisory on omega-3 for cardiovascular disease states: "Prescription omega-3 fatty acid medications are generally well tolerated" and notes the most common adverse effects as gastrointestinal symptoms and a modest increase in LDL-C with some formulations [8]. No mention of PDE5 inhibitor interaction appears in that advisory.

The Endocrine Society and the American Urological Association do not list omega-3 as a compound requiring avoidance in men taking tadalafil for ED or BPH [12].

Practical Guidance: Taking Both Safely

Standard OTC Fish Oil (1 to 2 g EPA+DHA/day)

Men taking tadalafil for ED or BPH who want to add a standard OTC omega-3 supplement may do so without any special precautions beyond checking blood pressure at baseline and after 4 to 6 weeks. The pharmacokinetic safety is well-established, and the pharmacodynamic overlap at this dose is clinically minor.

Prescription-Strength Omega-3 (4 g/day Vascepa or Lovaza)

At 4 g/day, the blood-pressure-lowering effect of omega-3 becomes more clinically detectable. Men who start prescription omega-3 while already on tadalafil should have a blood pressure check within 4 weeks. A systolic reading below 100 mmHg warrants a conversation with the prescriber about adjusting either agent.

The antiplatelet effect at 4 g/day is also more consistent [4]. Men on aspirin or anticoagulants alongside tadalafil and high-dose omega-3 should notify their prescriber and may need more frequent INR monitoring if on warfarin.

Timing and Administration

No dose-separation window is required. Omega-3 is best absorbed with a fat-containing meal, so taking it with dinner (a common practice) is fine regardless of when tadalafil is taken [13].

A Note on Product Quality

Not all omega-3 supplements contain the labeled EPA and DHA amounts. A 2023 analysis of 45 commercially available fish oil products published in JAMA Network Open found that 32 of 45 products (71%) had total omega-3 content within 10% of label claims, but oxidation levels varied widely [13]. Choosing products with third-party certification (NSF International, USP, or IFOS) reduces the risk of rancid oil and inaccurate dosing.

This matters clinically because a man who believes he is taking 1 g EPA+DHA per day but is actually getting 3 g from an over-dosed product may unknowingly reach the threshold where antiplatelet effects become more consistent.